This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Perhaps no area of neurology has experienced the transforming changes of improved therapeutics more than neuroAIDS. From the inception of the AIDS epidemic in the 1980s through 1996, patients regularly presented with dreadful opportunistic complications due to severe immunodeficiency, as well as disabling cognitive impairment closely associated with advanced HIV disease involving the brain.1 Combination antiretroviral therapy (cART) was transforming, resulting in precipitous reduction in lethal opportunistic complications. At the same time, the AIDS dementia complex became a rare entity.2
The euphoria induced by this advance in therapeutics has been muted by emerging observations. For several years, multiple groups performing careful examination of patients receiving cART have noted that nearly half of the population remains mildly cognitively impaired when carefully evaluated and compared with normative populations.3–5 The etiology of this impairment is incompletely understood. That HIV continues to drive cognitive impairment remains plausible, perhaps enabled by the challenges of treatment of this virus beyond the blood–brain barrier …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Alert Me
Recommended articles
HIV-RELATED IMMUNE RECONSTITUTION CRYPTOCOCCAL MENINGORADICULITIS: CORTICOSTEROID RESPONSE
Selegiline and oxidative stress in HIV-associated cognitive impairment
Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort
Determinants of survival in progressive multifocal leukoencephalopathy